Dr. David Chan, MD
Hematology & Oncology (Hematology & Oncology Physician)
3285 Skypark Dr
Torrance, CA 90505
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of California, Geffen School of Medicine (1979)
- Years since graduation
- 47
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 356
Licensed in California since 1980, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1979Medical school: University of California, Geffen School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
CA license G43553 (first issued 1980; current) -
Medical Oncology Physician
CA license G43553 (first issued 1980; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Torrance Memorial Medical Center Torrance, CA
- Providence Little Company of Mary Med Ctr Torrance Torrance, CA
Medical groups
- Torrance Health Association Inc (299 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 356
- Services billed
- 111,376
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, heparin sodium, (heparin lock flush), per 10 units | 4,500 | 20 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 923 | 295 |
| Injection, granisetron hydrochloride, 100 mcg | 880 | 13 |
| Established patient office or other outpatient visit, 30-39 minutes | 773 | 344 |
| Injection, zoledronic acid, 1 mg | 537 | 79 |
| Injection, dexamethasone sodium phosphate, 1 mg | 448 | 14 |
| Administration of chemotherapy into vein, 1 hour or less | 235 | 23 |
| Established patient office or other outpatient visit, 40-54 minutes | 220 | 76 |
| Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | 197 | 37 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 196 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Torrance, CA | 320 |
| Raloxifene Hcl Other prescribers in Torrance, CA | 97 |
| Letrozole Other prescribers in Torrance, CA | 78 |
| Verzenio (abemaciclib) | 47 |
| Trazodone Hcl Other prescribers in Torrance, CA | 41 |
| Tamoxifen Citrate Other prescribers in Torrance, CA | 34 |
| Orserdu (elacestrant hcl) | 32 |
| Exemestane | 29 |
| Xarelto (rivaroxaban) Other prescribers in Torrance, CA | 28 |
| Ibrance (palbociclib) | 26 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 16 payments worth $505 in total to this clinician.
| Insightec,inc | $147 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $137 |
| Puma Biotechnology, Inc. | $89.61 |
| Array Biopharma Inc | $80.11 |
| Accord Healthcare, Inc. | $30.16 |
| E.r. Squibb & Sons, L.l.c. | $20.41 |
| Food and Beverage | $505 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $381,283 in research payments for these studies, mostly to the institutions running them.
- A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherap…
AstraZeneca Pharmaceuticals LP - Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
Daiichi Sankyo Inc. · Completed · NCT03734029 - Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence
Novartis Pharmaceuticals Corporation - A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual…
AstraZeneca Pharmaceuticals LP - Randomized doubleblind phase 3 study of tucatinib or placebo in combination with adotrastuzumab emtansine TDM1 for subjects with unresectable locallyadvanced or metastatic HER2 breast cancer HER2CLIMB02
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.